绗竴涓夊叡鏄竴瀹朵负绀句細鍙寔缁彂灞曞仛璐＄尞鐨勫垱鏂板瀷鍏ㄧ悆鍖荤枟淇濆仴鍏徃锛岃嚧鍔涗簬鍙戠幇銆佸紑鍙戝拰鎻愪緵鏂扮殑鏍囧噯鐤楁硶锛屼互鎻愰珮涓栫晫鍚勫湴鎮ｈ€呯殑鐢熸椿璐ㄩ噺銆傜涓€涓夊叡涓撴敞鍒惰嵂琛屼笟120浣欏勾锛屽嚟鍊熷叾涓栫晫涓€娴佺殑绉戝鍜屾妧鏈紝涓虹檶鐥囥€佸績琛€绠＄柧鐥呭拰鍏朵粬鍖荤枟闇€姹傝繙鏈緱鍒版弧瓒崇殑鐤剧梾鎮ｈ€呯爺鍙戞柊鐨勬不鐤楁柟娉曞拰鍒涙柊鑽墿銆傚娆蹭簡瑙ｆ洿澶氫俊鎭紝璇疯闂�www.daiichisankyo.com<\/a>銆�<\/p> \n

\n \n \n \n \n \n \n \n \n \n
[1] Bardia A, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2鈥�) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. ESMO Congress 2023. LBA11.<\/span><\/p> <\/td> \n <\/tr> \n
[2] National Cancer Institute. SEER cancer stat facts: female breast cancer subtypes. Accessed September 2023.<\/span><\/p> <\/td> \n <\/tr> \n
[3] Iqbal N, et al. Mol Biol Int<\/i>. 2014;852748.<\/span><\/p> <\/td> \n <\/tr> \n
[4] Lin M, et al. J Cancer<\/i>. 2020; 10.7150\/jca.48944.<\/span><\/p> <\/td> \n <\/tr> \n
[5] Lloyd M R, et al. Clin Cancer Res.<\/i> 2022; 28(5):821-30.<\/span><\/p> <\/td> \n <\/tr> \n
[6] Goldenberg D, et al. Oncotarget<\/i>. <\/i>2018;9(48): 28989-29006.<\/span><\/p> <\/td> \n <\/tr> \n
[7] Vidula N, et al. Breast Cancer Res Treat<\/i>. 2022 Aug;194(3):569-575.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
\n<\/div>"]; $("#dvExtra").html(content_array[0]);})();